Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTP435 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| TTP435 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TTP435 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male or female volunteers, aged 18 to 65 years, inclusive. * Subjects must be obese (class 1: BMI of 30.0 to 34.9 kg/m2 or class 2: BMI of 35 to 39.9 kg/m2 in non-Asians and BMI of 27.0 - 31.9 kg/m2 or 32.0 - 36.9 kg/m2 in Asians) at the Screening Visit. * Female subjects must...
Top 20 of 32 competitors
TTP435 is an investigational small molecule being developed for the management of obesity and weight loss. It is currently in Phase 2 clinical development, with one completed trial that enrolled 100 participants in the United States and Canada.
TTP435 targets agouti-related protein (AgRP), a neuropeptide involved in appetite regulation. By inhibiting AgRP, the drug aims to manage obesity and promote weight loss. This mechanism was evaluated in a Phase 2 safety study.
TTP435 is being developed by vTv Therapeutics Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol VTVT. The drug is currently in Phase 2 clinical development for obesity.
TTP435 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not been approved by regulatory authorities.
TTP435 has one completed clinical trial, identified as NCT00779519. This Phase 2 study, titled 'Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss,' enrolled 100 participants in the United States and Canada.
TTP435 is an inhibitor of agouti-related protein (AgRP), a target involved in appetite regulation. The drug is being studied for its potential to manage obesity and promote weight loss. It is a small molecule developed by vTv Therapeutics Inc.